Indications
Spasms of smooth muscle associated with diseases of the biliary tract: cholecystolithiasis, cholangiolithiasis, cholecystitis, pericholecystitis, cholangitis, papillitis.

Spasms of smooth muscles in diseases of the urinary tract: nephrolithiasis, urethrolithiasis, pyelitis, cystitis, tenesmus of the bladder.

As an adjunctive treatment:

in spasms of smooth muscles of the gastrointestinal tract: peptic ulcer disease of the stomach and duodenum, gastritis, cardio- and/or pylorospasm, enteritis, colitis, spastic colitis with constipation and irritable bowel syndrome, accompanied by flatulence;
tension headache;
in gynecological diseases: dysmenorrhea.
Contraindications
Hypersensitivity to Drotaverine or to any component of the drug.Severe hepatic, renal or heart failure (low cardiac output syndrome).

Dosage and Administration
Adults: the recommended dose is 120-240 mg per day in 2-3 doses.

Children: the use of Drotaverine in children has not been studied in clinical trials; however, if the use of Drotaverine is necessary:

for children 6-12 years old the maximum daily dose is 80 mg (divided into 2 doses)
for children over 12 years old the maximum daily dose is 160 mg (divided into 2-4 doses).
There are no data on the use of the drug in children under 6 years old.

Before using No-shpa® tablets in a dosing container, remove the protective tape under the lid and the protective label on the bottom of the container.

Kids. The drug is contraindicated in children under 6 years of age.

Clinical studies on the use of the drug in children have not been conducted.